Predictive Value of Blood Eosinophils for Immunotherapy in NSCLC, 316 Patients (2016-2024)

Huan Zhang's retrospective study includes data from 316 consecutive patients with unresectable stage III–IV non-small cell lung cancer treated with immune checkpoint inhibitor-based regimens at Harbin Medical University Cancer Hospital between 2016 and 2024. The dataset contains peripheral blood eosinophil counts and percentages measured at baseline and after treatment cycles, correlated with overall survival, progression-free survival, and immune-related adverse events. The study was last updated on 2026-04-30 and is shared under a CC-BY-4.0 license.

Use Cases

• Modeling overall survival based on changes in absolute eosinophil count from baseline to cycle 4.
• Predicting progression-free survival using optimal cut-offs for eosinophil percent at cycle 4.
• Assessing the risk of immune-related adverse events based on eosinophil levels at cycles 2 and 4.
• Validating peripheral blood eosinophil-related indices as practical biomarkers for immunotherapy efficacy and safety.

Strengths

• Includes data from 316 consecutive patients, providing a real-world cohort.
• Contains longitudinal measurements of eosinophil counts at baseline, cycle 2, and cycle 4.
• Associations with clinical endpoints (OS, PFS, irAEs) are supported by multivariable Cox analysis with reported p-values and hazard ratios.
• Specific optimal cut-off values for key biomarkers (e.g., 0.22×10^9/L for cycle 4 AEC) are provided.

Limitations

• Row count and column-level documentation are unknown, limiting suitability assessment.
• Data is from a single institution (Harbin Medical University Cancer Hospital), which may limit generalizability.
• The dataset is small (38.7 KB), indicating limited scope.

Provenance

Source

Harbin Medical University Cancer Hospital

Collection Method

Retrospective study of consecutive patients.

Time Range

2016–2024

Freshness

Last updated 2026-04-30 05:41:46; freshness should be verified.

Geography

Likely China (based on hospital location).